Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Pharma, Inc. (NASDAQ: BBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BridgeBio is a biopharmaceutical company focused on medicines for genetic diseases, and its filings give detailed insight into clinical milestones, financial condition, capital structure, and corporate governance.
Current reports on Form 8-K are a key source of information for BBIO. The company uses 8-K filings to report material events such as positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 and for BBP-418 in LGMD2I/R9, quarterly business updates and financial results, and significant agreements like royalty interest purchase and sale arrangements tied to acoramidis royalties in Europe. 8-Ks also describe shareholder votes on amendments to the certificate of incorporation, stock incentive plans, and other governance matters.
Investors can also review filings that discuss BridgeBio’s financing activities, including proposed offerings of convertible senior notes and the terms, ranking, and convertibility features of such instruments, as well as transactions that monetize future royalty streams. These documents help explain how the company funds commercialization of Attruby (acoramidis) and its broader development pipeline.
On Stock Titan, BBIO filings are updated as new documents are posted to EDGAR. AI-powered summaries highlight the main points of long forms such as 8-Ks, so readers can quickly see why a filing was made, what agreements or results were disclosed, and how it may relate to BridgeBio’s clinical programs, ATTR-CM franchise, or capital structure. Users can drill down into individual filings for full legal and financial detail, including exhibits referenced in the company’s reports.
BridgeBio Pharma’s Chief Executive Officer, Kumar Neil, reported indirect open-market sales of the company’s common stock on February 10–11, 2026. The transactions were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co-trustee, under a Rule 10b5-1 sales plan adopted on March 31, 2025. Individual trades included, for example, 14,201 shares sold at a weighted average price of $71.8018 per share and 7,806 shares at $70.6887 per share. After these sales, the trusts continued to hold large indirect positions, including 675,686 and 4,478,447 shares, and the Form 4 notes that the reporting person disclaims beneficial ownership beyond any pecuniary interest.
BridgeBio Pharma reported positive topline Phase 3 results from its PROPEL 3 trial of oral infigratinib in children with achondroplasia. The study met its primary endpoint, showing a statistically significant improvement in annualized height velocity at Week 52 (p<0.0001), with a mean treatment difference versus placebo of +2.10 cm/year and an LS mean of +1.74 cm/year.
The trial also met a key secondary endpoint, improving height Z-score, and showed the first statistically significant improvement in body proportionality versus placebo in children younger than 8 years. Oral infigratinib was generally well tolerated, with no treatment-related serious adverse events or discontinuations reported.
Based on these results, BridgeBio plans to submit a New Drug Application and Marketing Authorization Application for infigratinib for achondroplasia in the second half of 2026 and to accelerate development in hypochondroplasia, including ongoing and planned Phase 3 programs.
BridgeBio Pharma completed a private offering of $632.5 million in 0.75% Convertible Senior Notes due 2033 to qualified institutional buyers under Rule 144A. The notes pay 0.75% interest semiannually, mature on February 1, 2033, and can be settled in cash, stock, or a combination at the company’s election.
BridgeBio received approximately $619.3 million in net proceeds, which it plans to use mainly to repurchase, settle conversion obligations for, or repay a portion of its 2.50% Convertible Senior Notes due 2027, as well as for general corporate purposes. Concurrently with the closing, it used about $82.5 million of cash on hand to repurchase 1,081,825 shares of common stock at $76.26 per share from certain note purchasers.
The initial conversion rate is 9.0435 shares per $1,000 principal amount (an initial conversion price of about $110.58 per share), with potential adjustment and an increased rate in certain corporate events. A maximum of 8,293,972 shares may initially be issued upon conversion based on a maximum conversion rate of 13.1130 shares per $1,000 principal amount.
BridgeBio Pharma, Inc. insider activity centers on trusts associated with its Chief Executive Officer. A Form 4 reports that on January 8 and 9, 2026, the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, for which the CEO is a co‑trustee, sold multiple blocks of BridgeBio common stock under a Rule 10b5‑1 sales plan adopted on March 31, 2025.
The reported weighted average sale prices for these transactions range from about $73.05 to $78.32 per share, with examples including 11,515 shares at a weighted average price of $73.6446 and 10,519 shares at $77.6086. Following the reported trades, the family irrevocable trust held 715,686 shares, the revocable trust held 4,518,447 shares, and 228,776 shares were held directly. The reporting person disclaims beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.
BridgeBio Pharma furnished an update with preliminary, unaudited financial figures for the quarter and fiscal year ended December 31, 2025. The company estimates it had approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. It also estimates net product revenue of $146.0 million for the fourth quarter of 2025 and $362.4 million for the full year 2025.
The company emphasized that these numbers are preliminary and subject to change as the year-end audit is completed. BridgeBio also presented a business update at the 44th Annual J.P. Morgan Healthcare Conference, and made its presentation slides available as an exhibit and on its website.
A holder of BridgeBio Pharma (BBIO) common stock filed a notice of intent to sell 120,000 shares under Rule 144. The shares are common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,912,400 and 192,708,813 common shares outstanding. The seller originally acquired these 120,000 shares on 03/26/2016 via conversion of management incentive units from the issuer.
The filing also lists recent sales made under Rule 10b5-1 trading plans over the prior three months by Neil Kumar and related trusts. Examples include 30,011 common shares sold on 12/15/2025 for gross proceeds of $2,239,901.00, and 20,000-share transactions on multiple dates in November and October 2025 by revocable and irrevocable trusts associated with the same address. The signer represents they are not aware of undisclosed material adverse information about the issuer.
The Form 144 notice for BBIO discloses a planned sale of 100000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 7427000.00. These shares are part of a class with 192708813 shares outstanding and are expected to be sold on or about 01/08/2026 on the NASDAQ.
The securities to be sold were acquired on 03/26/2016 via conversion of management incentive units from the issuer, with no gift indicated. The notice also lists multiple Rule 10b5-1 sales of common stock during the prior three months for accounts associated with NEIL KUMAR and related trusts, each disclosing the date, number of shares sold, and gross proceeds.
BridgeBio Pharma's chief executive officer and director reported multiple stock transactions in December 2025. On December 12, 2025, 60,975 restricted stock units converted into common stock, and 30,964 shares were withheld to satisfy tax obligations linked to this vesting.
On December 15, 2025, the officer sold 28,311 shares at a weighted average price of $74.5997 and 1,700 shares at $75.2412 under a Rule 10b5-1 sales plan adopted on March 31, 2025. After these transactions, the officer directly owned 228,776 shares, with an additional 755,686 and 4,558,447 shares held indirectly through family trusts, subject to a disclaimer of beneficial ownership beyond any pecuniary interest.
BridgeBio Pharma, Inc. reported an insider equity transaction by its President and CFO. On 12/12/2025, 13,826 shares of the company’s common stock were withheld at $75.15 per share to cover the executive’s tax obligations related to equity compensation.
The tax withholding was connected to the vesting of 25,000 shares of common stock underlying the executive’s restricted stock units. Following this transaction, the reporting officer directly beneficially owns 369,004 shares of BridgeBio Pharma common stock.
BridgeBio Pharma, Inc. reported an equity transaction by its Chief Accounting Officer, Maricel Apuli. On 12/12/2025, 2,003 shares of common stock were withheld to satisfy the officer's tax obligation arising from the vesting of 3,944 restricted stock units. The transaction price reported for the withheld shares was $75.15 per share. After this withholding, the officer beneficially owned 128,294 shares of BridgeBio Pharma common stock in direct ownership.